ATYR vs. ATAI

Last updated Apr 1, 2026

Compare and contrast key facts about aTyr Pharma, Inc. (ATYR) and Atai Life Sciences N.V. (ATAI).

Performance

ATYR vs. ATAI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in aTyr Pharma, Inc. (ATYR) and Atai Life Sciences N.V. (ATAI). The values are adjusted to include any dividend payments, if applicable.

ATYR vs. ATAI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ATYR aTyr Pharma, Inc.	-0.40%	-78.37%	156.74%	-35.62%	-70.68%	66.00%
ATAI Atai Life Sciences N.V.	-13.45%	207.52%	-5.67%	-46.99%	-65.14%	-60.77%

Fundamentals

EPS ATYR : -$0.80 ATAI : -$2.72
PS Ratio ATYR : 384.40 ATAI : 210.21
Total Revenue (TTM) ATYR : $190.00K ATAI : $4.09M
Gross Profit (TTM) ATYR : -$34.17M ATAI : $3.08M
EBITDA (TTM) ATYR : -$76.54M ATAI : -$113.05M

Returns By Period

In the year-to-date period, ATYR achieves a -0.40% return, which is significantly higher than ATAI's -13.45% return.

ATYR

• 1D: 6.72%
• 1M: -18.73%
• YTD: -0.40%
• 6M: 8.12%
• 1Y: -74.17%
• 3Y*: -28.12%
• 5Y*: -29.78%
• 10Y*: -34.46%

ATAI

• 1D: 4.12%
• 1M: -2.48%
• YTD: -13.45%
• 6M: -33.08%
• 1Y: 160.29%
• 3Y*: 25.06%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ATYR vs. ATAI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATYR

ATYR Risk / Return Rank: 21
ATYR Sharpe Ratio Rank: 15
ATYR Sortino Ratio Rank: 29
ATYR Omega Ratio Rank: 29
ATYR Calmar Ratio Rank: 11
ATYR Martin Ratio Rank: 20

ATAI

ATAI Risk / Return Rank: 85
ATAI Sharpe Ratio Rank: 90
ATAI Sortino Ratio Rank: 88
ATAI Omega Ratio Rank: 84
ATAI Calmar Ratio Rank: 86
ATAI Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATYR vs. ATAI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for aTyr Pharma, Inc. (ATYR) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ATYR	ATAI	Difference
Sharpe ratio Return per unit of total volatility	-0.61	1.89	-2.50
Sortino ratio Return per unit of downside risk	-0.03	2.65	-2.68
Omega ratio Gain probability vs. loss probability	1.00	1.32	-0.33
Calmar ratio Return relative to maximum drawdown	-0.83	2.93	-3.76
Martin ratio Return relative to average drawdown	-1.16	5.49	-6.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ATYR vs. ATAI - Sharpe Ratio Comparison

The current ATYR Sharpe Ratio is -0.61, which is lower than the ATAI Sharpe Ratio of 1.89. The chart below compares the historical Sharpe Ratios of ATYR and ATAI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ATYR	ATAI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.61	1.89	-2.50
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.40	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.46	-0.36	-0.11

Correlation

The correlation between ATYR and ATAI is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ATYR vs. ATAI - Dividend Comparison

Neither ATYR nor ATAI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ATYR vs. ATAI - Drawdown Comparison

The maximum ATYR drawdown since its inception was -99.83%, which is greater than ATAI's maximum drawdown of -94.77%. Use the drawdown chart below to compare losses from any high point for ATYR and ATAI.

Drawdown Indicators

	ATYR	ATAI	Difference
Max Drawdown Largest peak-to-trough decline	-99.83%	-94.77%	-5.06%
Max Drawdown (1Y) Largest decline over 1 year	-90.15%	-48.06%	-42.09%
Max Drawdown (5Y) Largest decline over 5 years	-94.78%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.26%	—	—
Current Drawdown Current decline from peak	-99.80%	-82.20%	-17.60%
Average Drawdown Average peak-to-trough decline	-93.07%	-79.80%	-13.27%
Ulcer Index Depth and duration of drawdowns from previous peaks	64.91%	25.66%	+39.25%

Volatility

ATYR vs. ATAI - Volatility Comparison

aTyr Pharma, Inc. (ATYR) has a higher volatility of 21.76% compared to Atai Life Sciences N.V. (ATAI) at 20.69%. This indicates that ATYR's price experiences larger fluctuations and is considered to be riskier than ATAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ATYR	ATAI	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.76%	20.69%	+1.07%
Volatility (6M) Calculated over the trailing 6-month period	61.00%	53.14%	+7.86%
Volatility (1Y) Calculated over the trailing 1-year period	121.55%	85.60%	+35.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.77%	84.11%	-0.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.40%	84.11%	+1.29%

Financials